论文部分内容阅读
目的:研究乳腺癌人表皮生长因子受体α(HER2),p53与生存期的关系,探讨其成为乳腺癌临床康复预后指标的可行性。方法:采用免疫组化法检测185例乳腺癌标本的HER2和p53的表达,并对其生存时间随访。结果:①有10年内预后随访资料者120例,其中死亡28例,失访65例。②HER2,p53的阳性总表达率分别为:57.8%和47.6%。③HER2和p53各级生存率曲线比较,统计学上有显著性差异,P值均小于0.01。0～Ⅲ级均数得分为:11.9286,6.5500,-5.5556,-7.2273和9.6604,-8.0625,-27.9167,-4.0000。④HER2或p53过度表达均与生存期负相关(P<0.05,OR=1.566和P<0.01,OR=1.581)。⑤HER2联合p53过度表达与生存期负相关(P<0.05,OR=1.374和P<0.01,OR=1.566)。结论:乳腺癌患者HER2或p53阴性表达的生存率高于阳性表达者,无论是单独或者联合高表达都降低乳腺癌患者的生存时间,是乳腺癌预后不良的指标。
Objective: To study the relationship between the expression of epidermal growth factor receptor alpha (HER2), p53 and survival in breast cancer and explore its feasibility as a prognostic indicator of clinical rehabilitation in breast cancer. Methods: Immunohistochemistry was used to detect the expression of HER2 and p53 in 185 cases of breast cancer. The survival time was followed up. Results: ① There were 120 cases with follow-up data within 10 years, of which 28 cases died and 65 cases were lost to follow-up. ② The positive rates of HER2 and p53 were 57.8% and 47.6%, respectively. ③The survival rates of HER2 and p53 at different levels showed statistically significant differences, P values were less than 0.01.0 ~ Ⅲ grade mean scores were: 11.9286, 6.5500, -5.5556, -7.2273 and 9.6604, -8.0625, -27.9167 , -4.0000. ④ HER2 or p53 overexpression was negatively correlated with survival (P <0.05, OR = 1.566 and P <0.01, OR = 1.581). ⑤ HER2 combined p53 overexpression and survival was negatively correlated (P <0.05, OR = 1.374 and P <0.01, OR = 1.566). Conclusions: The survival rate of HER2 or p53 negative expression in breast cancer patients is higher than that of positive ones. Either alone or in combination with high expression can reduce the survival time of breast cancer patients, which is an indicator of poor prognosis of breast cancer.